Streetwise Reports (03/28/2024)
"Investors are salivating over the potential with [this company] right now," one newsletter editor/publisher wrote. Read on to discover why.
Streetwise Reports (03/27/2024)
Sadot Group Inc., an emerging player in the global food supply chain sector, announced its fourth quarter and full year 2023 financial results, noting that its consolidated revenue increased from 2022.
Streetwise Reports (03/27/2024)
Seabridge Gold Inc. recently put out a report card, detailing which of its 2023 goals were met, and shared information about upcoming catalysts, including a potential JV partner.
Streetwise Reports (03/27/2024)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
Streetwise Reports (03/27/2024)
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.